Skip to main content
Craig Portell, MD, Oncology, Charlottesville, VA

CraigAnthonyPortellMD

Oncology Charlottesville, VA

Hematologic Oncology

Associate Professor of Medicine, Division of Hematology/Oncology, University of Virginia

Dr. Portell is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Portell's full profile

Already have an account?

  • Office

    1240 Lee St
    Charlottesville, VA 22908
    Phone+1 434-924-9333
    Fax+1 434-244-7526

Summary

  • Dr. Craig Portell is an oncologist in Charlottesville, VA and is affiliated with Emily Couric Clinical Cancer Center and University of Virginia Medical Center. He received his medical degree from St Louis University School of Medicine and has been in practice 11 years. He specializes in hematologic oncology and is experienced in immunotherapy, chronic lymphoid leukemia, mantle cell lymphoma, waldenstrom's macroglobulinemia, and Non-Hodgkin Lymphoma.

Education & Training

  • Cleveland Clinic Foundation
    Cleveland Clinic FoundationFellowship, Hematology and Medical Oncology, 2010 - 2013
  • Loyola University Medical Center
    Loyola University Medical CenterResidency, Internal Medicine, 2006 - 2009
  • Saint Louis University School of Medicine
    Saint Louis University School of MedicineClass of 2006

Certifications & Licensure

  • VA State Medical License
    VA State Medical License 2013 - 2026
  • OH State Medical License
    OH State Medical License 2010 - 2014
  • IL State Medical License
    IL State Medical License 2006 - 2011
  • American Board of Internal Medicine Hematology
  • American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

  • CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013-2014

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • The Phase 3 DUO Trial: Duvelisib Versus Ofatumumab in Relapsed and Refractory CLL/SLL  
    Matthew S Davids, Ian W Flinn, Craig A Portell, Nicole Lamanna, Scott Lunin, Amanda F Cashen, Blood

Abstracts/Posters

  • Efficacy of Therapies Following Venetoclax Discontinuation in CLL: Focus on B-Cell Receptor Signal Transduction Inhibitors and Cellular Therapies
    Craig A. Portell, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
  • Current Selection Patterns, Toxicities and Outcomes of Pre-Transplant Salvage Treatment Regimens in Patients with Relapsed/Refractory Hodgkin Lymphoma: Results of a Mu...
    Craig A. Portell, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
  • Outcomes of Patients with Newly-Diagnosed Burkitt Lymphoma (BL) and Central Nervous System (CNS) Involvement Treated in the Modern Era: A Multi-Institutional Real-Worl...
    Craig A. Portell, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
  • Join now to see all

Lectures

  • Multi-Institution Phase I/Ib Continual Re-Assessment Study to Identify the Optimal Dose of of Ibrutinib (IBR) and Venetoclax (VEN) in Relapsed or Refractory Mantle Cel... 
    61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019

Press Mentions

  • When Chemo Failed, CAR T-cell Therapy Took Away a Father’s Cancer
    When Chemo Failed, CAR T-cell Therapy Took Away a Father’s CancerSeptember 22nd, 2022
  • Venetoclax with Standard Chemo-Immunotherapy Induced a High Response Rate as First-Line Treatment for Mantle Cell Lymphoma and Was Generally Well Tolerated, a PrECOG Early-Phase Trial Shows
    Venetoclax with Standard Chemo-Immunotherapy Induced a High Response Rate as First-Line Treatment for Mantle Cell Lymphoma and Was Generally Well Tolerated, a PrECOG Early-Phase Trial ShowsDecember 13th, 2023

Professional Memberships